BIOQUAL, Inc. BIOQ

BIOQ Company Overview

BIOQUAL, Inc. is a privately held contract research organization (CRO) focused on preclinical and translational research services for infectious diseases, immunology, and biodefense-related programs. The company operates primarily within the biotechnology, pharmaceutical research, and biomedical services industries, supporting government agencies, academic institutions, and commercial biopharmaceutical companies. BIOQUAL is particularly recognized for its work in nonhuman primate (NHP) research, virology testing, vaccine evaluation, and regulated laboratory services associated with emerging infectious diseases including HIV, influenza, RSV, SARS-CoV-2, and other viral pathogens.

The company’s primary revenue drivers are fee-based research services, laboratory testing, animal model development, and support for vaccine and therapeutic development programs. BIOQUAL has developed a specialized position in high-containment infectious disease research through its laboratory infrastructure, GLP-compliant capabilities, and expertise in translational animal models. Founded in the late 1980s, the company evolved from a niche biomedical testing organization into a specialized infectious disease CRO serving both U.S. government-funded programs and private-sector drug development efforts. Publicly available information indicates that BIOQUAL has maintained a strong focus on biodefense and pandemic preparedness research throughout its expansion.